Aeterna Zentaris Inc. (TSE:AEZS) has released an update.
Aeterna Zentaris Inc. has received final court approval to merge with Ceapro Inc. in a strategic all-stock merger of equals, with completion expected in the second quarter of 2024 pending all necessary approvals. The merger aims to combine Aeterna’s expertise in specialty biopharmaceuticals and Ceapro’s plant-based extraction and active ingredient production, promising to address significant unmet medical needs and enhance shareholder value.
For further insights into TSE:AEZS stock, check out TipRanks’ Stock Analysis page.
